Intravitreal aflibercept for proliferative diabetic retinopathy - Authors' reply.

Sivaprasad, Sobha; Prevost, A Toby; Vasconcelos, Joana; Riddell, Amy; Hykin, Philip

Sivaprasad, Sobha; Prevost, A Toby; Vasconcelos, Joana; Riddell, Amy; Hykin, Philip.

Afiliação

Sivaprasad S; National Institute for Health Research, Moorfields Biomedical Research Centre, London EC1V 2PD, UK. Electronic address: Sobha.sivaprasad@moorfields.nhs.uk.
Prevost AT; Imperial Clinical Trials Unit, School of Public Health, Imperial College London, London, UK.
Vasconcelos J; Imperial Clinical Trials Unit, School of Public Health, Imperial College London, London, UK.
Riddell A; King's Clinical Trials Unit at King's Health Partners, King's College London, London, UK.
Hykin P; National Institute for Health Research, Moorfields Biomedical Research Centre, London EC1V 2PD, UK.

Lancet ; 390(10108): 2141-2142, 2017 11 11.

Article em En | MEDLINE | ID: mdl-29143752

Assuntos

Retinopatia Diabética; Receptores de Fatores de Crescimento do Endotélio Vascular; Inibidores da Angiogênese; Bevacizumab; Humanos; Proteínas Recombinantes de Fusão; Fator A de Crescimento do Endotélio Vascular

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Fatores de Crescimento do Endotélio Vascular / Retinopatia Diabética Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google